Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Apr 21;102(16):e33609.
doi: 10.1097/MD.0000000000033609.

Efficacy and safety of vesatolimod in chronic hepatitis B: A systematic review and meta-analysis

Ibrahim Omer  1   2 , Noorah Abuthiyab  1   2 , Basil Al-Omari  1   2 , Tala Aletani  1   2 , Manar Betar  1   2 , Nura Alzaid  1   2 , Alqassem Y Hakami  1   2
Affiliations
Meta-Analysis

Efficacy and safety of vesatolimod in chronic hepatitis B: A systematic review and meta-analysis

Ibrahim Omer et al. Medicine (Baltimore). .

Abstract

Background: Vesatolimod is a toll-like receptor (TLR) agonist that is thought to suppress chronic hepatitis B (HBV) infection. This systematic review aimed to assess the safety and efficacy of vesatolimod in treating chronic hepatitis B.

Methods: We included randomized clinical trials (RCTs) that assessed vesatolimod in patients with hepatitis B infection without hepatocellular carcinoma or liver transplantation and with reported levels of hepatitis B surface antigen (HBsAg) or liver transaminases post-intervention. We searched MEDLINE, SCOPUS, Springer, Google Scholar, ClinicalTrials.gov, and Cochrane Central Register of Clinical Trials for all related articles during May 2022. Two independent authors screened articles for inclusion, and discrepancies were resolved by consensus and a third reviewer. Two independent reviewers assessed studies included in this systematic review using the Critical Appraisal Skills Programme checklist for RCTs.

Results and conclusion: Only 4 were considered eligible from 391 articles identified through our search. All eligible studies did not report any clinically significant outcomes following the use of vesatolimod, as evidenced by the persistence of HBsAg. However, vesatolimod was associated with induction of interferon-stimulated genes (ISGs) and only mild side effects, warranting further studies to evaluate its potential for future use as a safe, tolerable anti-HBV medication. No significant differences were noted amongst trials included in either of Vesatolimod doses (Vesatolimod 1 mg, RR = 0.99, 95% CI 0.76-1.30, P = .95, I2 = 0%; Vesatolimod 2 mg, RR = 1.06, 95% CI 0.82-1.37, P = .66, I2 = 0%; Vesatolimod 4 mg, RR = 1.06, 95% CI 0.82-1.37, P = .66, I2 = 0%;), further suggesting its comparable safety in comparison to oral antiviral agents.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram. PRISMA = Preferred Reporting of Systematic Reviews and Meta-Analyses.
Figure 2.
Figure 2.
Treatment-emergent adverse events (TEAEs) for 1-mg Vesatolimod.
Figure 3.
Figure 3.
Treatment-emergent adverse events (TEAEs) for 2-mg Vesatolimod.
Figure 4.
Figure 4.
Treatment-emergent adverse events (TEAEs) for 4-mg Vesatolimod.
Figure 5.
Figure 5.
Treatment-emergent adverse events (TEAEs) for 1-mg Vesatolimod.
Figure 6.
Figure 6.
Treatment-emergent adverse events (TEAEs) for 2-mg Vesatolimod.
Figure 7.
Figure 7.
Treatment-emergent adverse events (TEAEs) for 4-mg Vesatolimod.
See this image and copyright information in PMC

References

    1. World Health Organization. Hepatitis B. World Health Organization. 2001. Retrieved May 1, 2022, from. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
    1. Zampino R, Boemio A, Sagnelli C, et al. . Hepatitis B virus burden in developing countries. World J Gastroenterol. 2015;21:11941–53. - PMC - PubMed
    1. Shih C, Yang CC, Choijilsuren G, et al. . Hepatitis B virus. Trends Microbiol. 2018;26:386–7. - PubMed
    1. Centers for Disease Control and Prevention. Hepatitis B - faqs, Statistics, data, & guidelines. Centers for Disease Control and Prevention. 2023, March 9. Retrieved May 1, 2022, from. Available at: https://www.cdc.gov/hepatitis/hbv/index.htm#:~:text=Hepatitis%20B%20is%2....
    1. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053–63. - PubMed

MeSH terms